Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

So-called GLP-1 supplements, named to echo the class of glucagon-like peptide-1 agonist drugs that includes Wegovy and Zepbound, are likely to be ineffective for weight loss. “If you can buy it ...

Patients using GLP-1 receptor agonists appear to have a lower risk of age-related macular degeneration and primary open-angle glaucoma. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs ...